CD33 and acute myeloid leukemia: AMV564, another BiTE construct with specificity to CD33 on target cells and CD3 on effector T-cells is currently undergoing phase 1 dose escalation study in R/R AML patients that have undergone at least 1–2 lines of prior induction regimens, with preliminary data showing a 49% reduction in bone marrow blasts [96].